☆ 4.7 Article

Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Neil Chanchlani et al.

Summary: Anti-TNF treatment is associated with lower seroprevalence of SARS-CoV-2 nucleocapsid antibodies and antibody reactivity compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels suggest a causal relationship, though other factors like combination therapy with immunomodulators may have influenced the results.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Aminosalicylates and COVID-19: Facts or Coincidences?

Fernando Magro et al.

GASTROENTEROLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

What Is the Incidence of COVID-19 in Patients With IBD in Western Countries?

Carlos Taxonera et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

Jordan E. Axelrad et al.

Summary: This case series study found that severe outcomes of COVID-19 after infection in patients with IBD were rare, and comparable to similarly aged individuals in the general population.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Ryan C. Ungaro et al.

Summary: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19, while no significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study

Mohamed Attauabi et al.

Summary: Patients with immune-mediated inflammatory diseases, including IBD, were less susceptible to COVID-19 compared to patients without such diseases, and use of immunosuppressive therapies or disease activity of IBD did not affect the disease course of COVID-19.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Medicine, General & Internal

Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19

Xiao-Zhi Li et al.

Summary: In patients with inflammatory bowel disease (IBD), the expression of intestinal ACE2 is influenced by intestinal inflammation, with different alterations in the ileum and colon. Colonic ACE2 expression is downregulated after anti-TNF alpha therapy in patients responding to treatment, and patients with severe histologically active disease have significantly higher ACE2 expression compared to those with moderate and mild histologically active disease.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden

Jonas F. Ludvigsson et al.

Summary: While individuals with IBD were more likely to be admitted to hospital for COVID-19 than the general population, the risk of severe COVID-19 was not higher.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Article Gastroenterology & Hepatology

Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System

Nabeel Khan et al.

Summary: In a nationwide cohort of patients with IBD, vedolizumab and corticosteroids were associated with an increased risk of SARS-CoV-2 infection. Except for corticosteroids, no medications including mesalazine were associated with an increased risk of severe COVID-19.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.

GUT (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease

Valeriya Pozdnyakova et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Erica J. Brenner et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

COVID-19 and immunomodulation in IBD

Markus F. Neurath

GUT (2020)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

Cristina Bezzio et al.

GUT (2020)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce

F. Magro et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Article Medicine, General & Internal

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Mariangela Allocca et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Review Gastroenterology & Hepatology

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

Geert D'Haens et al.

GASTROENTEROLOGY (2007)

Add to Collection

Article Immunology

Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ

C Rousseaux et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.